PREVIOUS ISSUE NEXT ISSUE
February 2018 FebCVAlfr.png
Substance P: Dry eye and allergy’s mixed signal or missing link?Inflammation may lead to heightened peripheral sensitization and stimulation through a developing concept in which neuroimmune cross-talk causes the confounding interplay of both signs and symptoms in dry eye and allergic disease.
Learning how to manage scared noncompliant patientsPatients can enter your practice with a variety of fears regarding their vision problems. Benjamin P. Casella, OD, FAAO, and chief optometric editor of Optometry Times, explains the importance of quelling patients' fears and making them comfortable during their exam.
How artificial intelligence may transform optometryArtificial intelligence (AI) is evolving around us. Thomas A. Wong, OD, looks at how AI has impacted our world and how it is set to impact patient treatment in optometry.
Q&A: Cheryl Donnelly, CEO, British Contact Lens AssociationCheryl Donnelly, CEO of the British Contact Lens Association, talks about learning from U.S. ODs, focusing on contact lenses, and shivering in Red Square in the latest Optometry Times Q&A.
How the Japanese treat allergic conjunctivitisMichael Cooper, OD, takes a look at how the Japanese treat allergic conjunctivitis to gain a different perspective on treatments. What he finds is that we aren't so different after all.
Why I changed what I tell patients about refractive surgeryRefractive surgery is no stranger to evolving technology and research. Jim Owen, OD, MBA, FAAO, explains how recent research has changed the way he positions laser vision correction with his patients.
Knowing the OD's role in substance abuseThe significant healthcare dilemmas of substance use pose challenges to our society. Michael W. Ohlson, OD, FAAO, discusses an optometrist's role in substance abuse treatment.
PREVIOUS ISSUE NEXT ISSUE